Icon
+91 94997 68112
Login Register

LIFYORLI (COPACKAGED) - (100MG;25MG; CAPSULE)

RELACORILANT None
100MG;25MG; CAPSULE
Less Than $1000 mn
None None
None None
None None
LIFYORLI is a glucocorticoid receptor antagonist indicated in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab.
Yes
LIFYORLI (COPACKAGED) Patent 1 Patent 2 Patent 3 Patent 4 Patent 5 Patent 6 Patent 7 Patent 8 Patent 9 Patent 10
*** *********

Download ParaIV Report

Download ParaIV Detailed Report

To get detailed report Contact Us

ParaIV Advanced Search






Drug Name Generic Name Dosage Route of Administration Probable FTF Known Para IV Filers Other ANDA Developers

Please contact contact@researchdelta.com to get more details.

Headquarters

Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023

+91 94997 68112

nimish@researchdelta.com

Products & Services

Para IV GenUS Pharmalysis Consulting Valuation

Quick Links

Home About Career Media Coverage Contact
© Research Delta, All Right Reserved.   Privacy Policy.   Terms and Conditions.